These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38574417)

  • 1. Prediction of viral protease inhibitors using proteochemometrics approach.
    Karasev DA; Sobolev BN; Filimonov DA; Lagunin A
    Comput Biol Chem; 2024 Jun; 110():108061. PubMed ID: 38574417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening.
    Federico LB; Silva GM; da Silva Hage-Melim LI; Gomes SQ; Barcelos MP; Galindo Francischini IA; Tomich de Paula da Silva CH
    Future Med Chem; 2021 Aug; 13(16):1353-1366. PubMed ID: 34169729
    [No Abstract]   [Full Text] [Related]  

  • 3. 3D proteochemometrics: using three-dimensional information of proteins and ligands to address aspects of the selectivity of serine proteases.
    Subramanian V; Ain QU; Henno H; Pietilä LO; Fuchs JE; Prusis P; Bender A; Wohlfahrt G
    Medchemcomm; 2017 May; 8(5):1037-1045. PubMed ID: 30108817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein structural heterogeneity: A hypothesis for the basis of proteolytic recognition by the main protease of SARS-CoV and SARS-CoV-2.
    Behnam MAM
    Biochimie; 2021 Mar; 182():177-184. PubMed ID: 33484784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases.
    Sivakumar D; Stein M
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34071582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of glutamine 189 flexibility in SARS-CoV-2 main protease: Lesson learned from in silico virtual screening of ChEMBL database and molecular dynamics.
    Said MA; Albohy A; Abdelrahman MA; Ibrahim HS
    Eur J Pharm Sci; 2021 May; 160():105744. PubMed ID: 33540040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.
    El-Hasab MAE; El-Bastawissy EE; El-Moselhy TF
    J Biomol Struct Dyn; 2018 May; 36(7):1713-1727. PubMed ID: 28531373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computer-Aided Prediction of the Interactions of Viral Proteases with Antiviral Drugs: Antiviral Potential of Broad-Spectrum Drugs.
    Ren P; Li S; Wang S; Zhang X; Bai F
    Molecules; 2023 Dec; 29(1):. PubMed ID: 38202808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Virtual Screening of the Antiviral Potentialities of Marine Polycyclic Guanidine Alkaloids against SARS-CoV-2 (COVID-19).
    El-Demerdash A; Metwaly AM; Hassan A; Abd El-Aziz TM; Elkaeed EB; Eissa IH; Arafa RK; Stockand JD
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33808721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral Drug Discovery: Norovirus Proteases and Development of Inhibitors.
    Chang KO; Kim Y; Lovell S; Rathnayake AD; Groutas WC
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30823509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
    Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
    Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyzing 3D structures of the SARS-CoV-2 main protease reveals structural features of ligand binding for COVID-19 drug discovery.
    Xu L; Chen R; Liu J; Patterson TA; Hong H
    Drug Discov Today; 2023 Oct; 28(10):103727. PubMed ID: 37516343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting Water Dynamics for Pharmacophore Screening.
    Schaller D; Pach S; Bermudez M; Wolber G
    Methods Mol Biol; 2021; 2266():227-238. PubMed ID: 33759130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease.
    Welsch C; Shimakami T; Hartmann C; Yang Y; Domingues FS; Lengauer T; Zeuzem S; Lemon SM
    Gastroenterology; 2012 Mar; 142(3):654-63. PubMed ID: 22155364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
    Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
    Molecules; 2020 May; 25(11):. PubMed ID: 32485894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteochemometrics modeling for prediction of the interactions between caspase isoforms and their inhibitors.
    Bastami Z; Sheikhpour R; Razzaghi P; Ramazani A; Gharaghani S
    Mol Divers; 2023 Feb; 27(1):249-261. PubMed ID: 35438428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
    Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
    Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Protein-ligand Interaction Based on Sequence Similarity and Ligand Structural Features.
    Karasev D; Sobolev B; Lagunin A; Filimonov D; Poroikov V
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33142754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generalized modeling of enzyme-ligand interactions using proteochemometrics and local protein substructures.
    Strömbergsson H; Kryshtafovych A; Prusis P; Fidelis K; Wikberg JE; Komorowski J; Hvidsten TR
    Proteins; 2006 Nov; 65(3):568-79. PubMed ID: 16948162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled Protein Activities with Viral Proteases, Antiviral Peptides, and Antiviral Drugs.
    Tague EP; McMahan JB; Tague N; Dunlop MJ; Ngo JT
    ACS Chem Biol; 2023 May; 18(5):1228-1236. PubMed ID: 37140437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.